The global spinal muscular atrophy treatment market size was valued at USD 5.09 billion in 2025 and is projected to grow from USD 5.99 billion in 2026 to USD 22.17 billion by 2034, registering a CAGR of 17.76% during the forecast period from 2026 to 2034. North America dominated the spinal muscular atrophy treatment market with a market share of 42.5% in 2025.
Spinal Muscular Atrophy (SMA) is a neuromuscular disorder possessing an autosomal recessive hereditary genetic profile. SMA is one of the fatal diseases with an incidence rate of 1 per 6,000 births to 1 per 10,000 births. The heterozygote carrier frequency of SMA is about 1 in every 40 to 60 people across the globe. It severely affects the motor neurons in the brain and spinal cord due to the homozygous mutation of the survival motor neuron gene 1 (SMN1). These motor neurons bring about the transfer of chemical and electrical charge to and fro from the voluntary muscles, present all over the body. Thereby, the affected motor neurons in the brain and spinal cord cause difficulty in performing several physical activities, including swallowing, crawling, and walking. SMA is a difficult disorder to diagnose, depending upon both histological and electrophysiological evidence of muscle denervation with uncertain results of treatment.
Download a Free Sample To learn more about this report,
Growing Shift Toward Presymptomatic Treatment Through Newborn Screening
Newborn screening is increasingly becoming an important pathway for expanding the Spinal Muscular Atrophy treatment market because disease-modifying therapies provide the greatest benefit when treatment begins before substantial motor-neuron loss occurs. Earlier genetic identification enables clinicians to initiate treatment before symptoms emerge, improving the potential for survival and motor-function preservation. This is shifting the treatment pathway from symptom-driven diagnosis toward population-level early detection and intervention.
Expansion of Gene Therapy Across Broader SMA Patient Populations
Gene therapy is becoming a more established component of SMA treatment as regulatory frameworks expand its use across wider age groups and disease presentations. This development broadens the addressable treatment population beyond infants and supports greater adoption of one-time genetic interventions alongside established disease-modifying approaches. Continued clinical follow-up is also increasing the evidence base surrounding long-term treatment outcomes and safety.
Earlier Diagnosis Increases Demand for Disease-Modifying SMA Therapies
Newborn screening allows affected infants to be identified before clinical deterioration, creating a direct pathway from diagnosis to treatment initiation. As screening programmes expand, the number of patients identified during the therapeutic window is expected to increase.
High Treatment Costs Limit Broader Access to SMA Therapies
The high cost of disease-modifying therapies remains a major restraint because SMA requires long-term clinical management in addition to drug treatment. Payers must consider medication costs, monitoring requirements and continuing multidisciplinary supportive care when determining reimbursement. These economic pressures can restrict treatment access, particularly in healthcare systems with limited rare-disease funding.
Expansion of Newborn Screening Creates a Larger Early-Treatment Population
Greater screening availability is particularly relevant in regions where delayed diagnosis continues to limit treatment outcomes. In July 2026, England announced nationwide expansion of SMA newborn screening, providing clinicians with a greater opportunity to identify affected babies before symptoms develop.
Unequal Global Access and Long-Term Care Requirements Complicate Market Expansion
The SMA treatment market faces challenges from uneven availability of therapies, differences in healthcare infrastructure and the need for lifelong multidisciplinary management. Although disease-modifying treatments have substantially changed SMA outcomes, access remains concentrated in better-resourced healthcare systems. Increasing numbers of patients surviving into adulthood also require treatment models that address long-term monitoring and transitions between pediatric and adult care.
Severe (Type I, Severe SMA or Werdnig-Hoffmann Disease) Dominated the Market with 46.8% Share in 2025
The severe (Type I, severe SMA or Werdnig-Hoffmann disease) segment accounted for the largest share of the global spinal muscular atrophy treatment market at 46.8% in 2025, driven by early disease onset, high treatment urgency, increasing newborn screening programs, and the availability of advanced disease-modifying therapies.
The intermediate (Type II or chronic SMA) segment continues to witness significant demand as patients require long-term disease management and supportive care. Mild (Type III, juvenile SMA or Kugelberg-Welander disease) is experiencing steady adoption of therapeutic interventions due to improved diagnosis and better treatment accessibility, while Type IV (adult SMA) remains an emerging segment supported by increasing awareness and advancements in adult neurological care.
Request Customizationto receive a tailored report.
Drugs are Projected to Register the Fastest Growth at a CAGR of 13.7%
The drugs segment is expected to expand at the highest CAGR of 13.7% during 2026–2034, driven by continuous advancements in disease-modifying therapies, expanding regulatory approvals, and increasing access to innovative pharmaceutical treatments for spinal muscular atrophy.
Gene therapy continues to play a transformative role by offering long-term therapeutic benefits through genetic correction. Medication and physical therapy remain essential components of comprehensive disease management, helping improve patient mobility and quality of life, while surgery is utilized in selected cases to address musculoskeletal complications. Other supportive treatment approaches continue to complement standard therapeutic strategies.
Intrathecal Dominated the Market with 42.9% Share in 2025
The intrathecal segment accounted for the largest share of the global spinal muscular atrophy treatment market at 42.9% in 2025, driven by the widespread use of intrathecal therapies that deliver medication directly into the cerebrospinal fluid for improved therapeutic effectiveness.
Oral administration is witnessing increasing adoption due to improved patient convenience and the growing availability of orally administered therapies. Parenteral administration also continues to gain traction with the introduction of advanced biologics and innovative treatment options for spinal muscular atrophy.
Abeparvovec is Projected to Register the Fastest Growth at a CAGR of 16.4%
The abeparvovec segment is anticipated to witness the fastest growth, registering a CAGR of 16.4% during 2026–2034, fueled by increasing adoption of gene replacement therapy, favorable clinical outcomes, and expanding treatment availability.
Nusinersen remains one of the most widely prescribed therapies due to its established clinical efficacy and broad adoption across healthcare settings. Onasemnogene continues to experience strong demand as healthcare providers increasingly adopt gene therapies for long-term disease management, while other emerging therapies are expanding treatment options through ongoing clinical research and innovation.
Intrathecal Dominated the Market with 44.3% Share in 2025
The intrathecal administration segment accounted for the largest share of the global spinal muscular atrophy treatment market at 44.3% in 2025, supported by the extensive use of intrathecal delivery for approved SMA therapies and its proven effectiveness in treating neurological disorders.
Subcutaneous administration is expected to gain momentum with the development of more patient-friendly therapies that simplify treatment delivery. Intraspinal administration continues to be utilized in specialized clinical settings, while other administration methods are being explored to improve treatment accessibility and patient outcomes.
Online Pharmacy is Projected to Register the Fastest Growth at a CAGR of 16.2%
The online pharmacy segment is expected to expand at the highest CAGR of 16.2% during 2026–2034, driven by increasing digital healthcare adoption, convenient medicine delivery services, and improved access to specialty therapies.
Hospital pharmacies continue to serve as the primary distribution channel owing to the specialized handling and administration requirements of SMA therapies. Retail pharmacies also play an important role by improving patient access to prescribed medications and supporting ongoing disease management.
Speak to an Analystto discuss market opportunities.
North America dominated the spinal muscular atrophy treatment market with a 42.5% share, valued at USD 2.16 billion in 2025. The region's leadership is driven by the high prevalence of rare disease diagnosis, strong adoption of advanced gene and disease-modifying therapies, favorable reimbursement policies, and substantial investments in rare disease research. Well-established healthcare infrastructure and increasing newborn screening programmes continue to support regional market growth.
The United States accounted for the largest share of the North American market in 2025. Growth is driven by increasing adoption of innovative gene therapies, strong government support for rare disease treatment, expanding newborn screening programmes, and the presence of leading biotechnology and pharmaceutical companies. Favorable reimbursement policies and ongoing clinical research further strengthen the country's market position.
Canada is witnessing steady market growth due to expanding access to advanced SMA therapies, increasing investments in rare disease research, growing awareness of early diagnosis, and supportive healthcare reimbursement programmes. Rising adoption of genetic testing is further contributing to market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 29.4% of the global spinal muscular atrophy treatment market, reaching USD 1.5 billion in 2025, and is projected to register the fastest CAGR of 15.6% during the forecast period. Market growth is supported by expanding newborn screening initiatives, increasing access to innovative therapies, rising investments in rare disease research, and favorable government policies for orphan drugs. Continuous advancements in genetic medicine continue to drive regional demand.
The United Kingdom is witnessing steady market growth owing to increasing adoption of advanced SMA therapies, expanding genetic screening programmes, rising investments in rare disease research, and strong support from the national healthcare system for innovative treatments.
Germany represents one of the largest markets in Europe, driven by advanced healthcare infrastructure, increasing availability of gene therapies, strong clinical research activities, and growing government support for rare disease management.
Asia Pacific accounted for 20.1% of the global spinal muscular atrophy treatment market, valued at USD 1.02 billion in 2025. The market is expanding due to improving healthcare infrastructure, increasing awareness of genetic disorders, rising adoption of newborn screening programmes, and growing investments in advanced biotechnology. Expanding access to innovative therapies is supporting regional market growth.
Japan is witnessing steady market growth due to its advanced healthcare system, increasing adoption of innovative gene therapies, expanding rare disease research, and strong government support for precision medicine and early diagnosis programmes.
China accounted for the largest share of the Asia Pacific market in 2025. Growth is supported by increasing healthcare expenditure, expanding access to rare disease treatments, growing investments in biotechnology, and rising awareness of early genetic diagnosis and screening.
The Middle East & Africa represented 3.4% of the global spinal muscular atrophy treatment market, totaling USD 0.17 billion in 2025. Rising investments in specialized healthcare services, improving access to rare disease diagnosis, expanding genetic testing capabilities, and increasing government healthcare spending are supporting regional market growth.
The UAE is a key market in the Middle East, driven by increasing investments in advanced healthcare infrastructure, expanding access to innovative genetic therapies, growing awareness of rare diseases, and strong government initiatives to improve specialized healthcare services.
Africa is witnessing gradual market growth, supported by improving healthcare infrastructure, increasing awareness of rare genetic disorders, expanding access to diagnostic services, and growing collaborations with international healthcare organizations. Countries such as South Africa, Egypt, and Kenya are creating long-term growth opportunities for market participants.
The global spinal muscular atrophy treatment market is highly competitive and innovation-driven, with major pharmaceutical and biotechnology companies competing across gene therapy, antisense oligonucleotide therapy, and other disease-modifying treatment approaches. The key players in the industry are Pfizer Inc., Biogen Idec, Boehringer Ingelheim GmbH, Ionis Pharmaceuticals Inc., AveXis Inc., Novartis AG, Cytokinetics Inc., F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals Inc., and others. The market is increasingly shaped by established therapies and the development of next-generation treatments designed to improve efficacy, durability, dosing convenience, and outcomes for patients with SMA.
The industry participants are focused on advancing gene replacement therapies, optimizing antisense oligonucleotide treatments, developing longer-acting therapies, and expanding treatment access across different age groups and disease stages. Companies are also investing in clinical trials, regulatory approvals, and alternative dosing approaches to differentiate their products in the rapidly evolving SMA treatment landscape.
Novartis AG: A Leading Market Player
Novartis AG is a leading player in the spinal muscular atrophy treatment market through its gene replacement therapy portfolio. The company's Itvisma (onasemnogene abeparvovec) provides a one-time gene replacement approach designed to address the underlying genetic cause of SMA by replacing the faulty SMN1 gene.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Medication Adherence Market Size, Share, Growth, 2034
Cytotoxic Drugs Market Size, Share, Growth, Analysis, Report, 2034
North America Aesthetic Medicine Market Size, Growth, Report to 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Asia Pacific Aesthetic Medicine Market Size, Top Share, Forecast to 2034
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com